Clinical Trials Browser

Phase 2/3 × Neoplasms × Clear all

NCT07005102 2026-05-22

A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Phase 2/3 Recruiting

Neoplasms

NCT06989437 2026-05-20

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

Phase 2/3 Recruiting

Gastrointestinal

Anorexia, Cachexia, Fatigue, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms, Weight Loss

NCT07112196 2026-05-20

VINCIT

Phase 2/3 Recruiting

Anorexia, Cachexia, Neoplasms, Weight Loss

NCT06800092 2026-05-11

SPARC

Phase 2/3 Not yet recruiting

Fatigue, Mental Fatigue, Neoplasms

NCT07000253 2026-05-07

OMEC-5

Phase 2/3 Recruiting

Gastrointestinal

Esophageal Neoplasms, Neoplasms, Stomach Neoplasms

NCT06085716 2026-05-05

Combination Therapy for Cancer Related Fatigue in Patients With Metastatic Cancers

Phase 2/3 Recruiting

Fatigue, Neoplasms

NCT01580618 2026-04-14

Tenecteplase (TNK) for Loculated Pleural Effusions in Patients With Malignancy

Phase 2/3 Terminated

20 enrolled 11 charts

Neoplasms, Pleural Effusion

NCT02491632 2026-03-18

Physical Activity and Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Advanced Cancer

Phase 2/3 Active not recruiting

90 enrolled 13 charts

Fatigue, Neoplasm Metastasis, Neoplasms, Recurrence

NCT07476443 2026-03-17

VitC-CoQ10

Phase 2/3 Not yet recruiting

Neoplasms

NCT07155187 2026-03-11

A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Phase 2/3 Recruiting

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT03435796 2026-03-04

Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells

Phase 2/3 Recruiting

Neoplasms

NCT07440290 2026-02-27

DETERMINE

Phase 2/3 Not yet recruiting

CNSEndocrineGastrointestinalGynecologicHead & NeckLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Thyroid Cancer, Papillary, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Glioma, Histiocytosis, Langerhans-Cell, Laryngeal Neoplasms, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Ovarian Neoplasms, Colorectal Neoplasms, Hematologic Neoplasms, Erdheim-Chester Disease, Thyroid Carcinoma, Anaplastic

NCT07408128 2026-02-13

P4E RCT

Phase 2/3 Not yet recruiting

Motor Activity, Neoplasms

NCT07321847 2026-01-07

INJECTABL-3

Phase 2/3 Not yet recruiting

Gastrointestinal

Neoplasm Metastasis, Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT07279792 2025-12-29

Implications of Post-Operative Irrigation Fluid's Osmolarity on the Recurrence of Non-Muscle Invasive Bladder Cancer Following Transurethral Resection

Phase 2/3 Completed

Neoplasms

NCT02783430 2025-12-16

KETAPAL

Phase 2/3 Completed

Depression, Neoplasms

NCT05786716 2025-12-02

DETERMINE

Phase 2/3 Recruiting

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther hematologic neoplasmThoracic

Urinary Bladder Neoplasms, Gallbladder Neoplasms, Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Skin Neoplasms, Colorectal Neoplasms, Hematologic Neoplasms

NCT05722886 2025-11-24

DETERMINE

Phase 2/3 Recruiting

LymphoidOther hematologic neoplasm

Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Hematologic Neoplasms

NCT05768178 2025-11-24

DETERMINE

Phase 2/3 Recruiting

CNSDermatologicEndocrineGastrointestinalGynecologicHead & NeckMyeloidOther hematologic neoplasmPlasma cellThoracic

Thyroid Cancer, Papillary, Carcinoma, Non-Small-Cell Lung, Glioma, Laryngeal Neoplasms, Melanoma, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Ovarian Neoplasms, Colorectal Neoplasms, Hematologic Neoplasms, Erdheim-Chester Disease, Thyroid Carcinoma, Anaplastic

NCT05770037 2025-11-24

DETERMINE

Phase 2/3 Recruiting

CNSGenitourinaryLymphoidOther hematologic neoplasm

Carcinoma, Renal Cell, Lymphoma, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neuroblastoma, Lymphoma, Large-Cell, Anaplastic, Hematologic Neoplasms

NCT05770102 2025-11-24

DETERMINE

Phase 2/3 Recruiting

DermatologicGastrointestinalGynecologicLymphoid

Lymphoproliferative Disorders, Melanoma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Colorectal Neoplasms, Endometrial Neoplasms

NCT05770544 2025-11-24

DETERMINE

Phase 2/3 Recruiting

CNSDermatologicLymphoidOther hematologic neoplasm

Brain Neoplasms, Glioma, Lymphoproliferative Disorders, Melanoma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Hematologic Neoplasms

NCT06988475 2025-11-24

DETERMINE

Phase 2/3 Recruiting

CNSGastrointestinalOther hematologic neoplasmSarcoma

Glioma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neuroblastoma, Sarcoma, Stomach Neoplasms, Hematologic Neoplasms

NCT05474846 2025-11-06

Combination Therapy for Treatment of Sleep Disturbance in Patients With Advanced Cancer

Phase 2/3 Recruiting

Anxiety Disorders, Depression, Fatigue, Neoplasms

NCT05694013 2025-10-22

ORIGAMA

Phase 2/3 Terminated

49 enrolled 14 charts

Neoplasms

NCT07202052 2025-10-07

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT)

Phase 2/3 Recruiting

LymphoidOther hematologic neoplasmPlasma cell

Infections, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Neoplasms, Neoplasms, Plasma Cell

NCT07202065 2025-10-07

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Dosing Immunoglobulin (Dose Ig)

Phase 2/3 Recruiting

LymphoidOther hematologic neoplasmPlasma cell

Infections, Leukemia, Lymphoma, Neoplasms, Neoplasms, Plasma Cell

NCT07202078 2025-10-07

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Starting Immunoglobulin (Start Ig)

Phase 2/3 Recruiting

LymphoidOther hematologic neoplasmPlasma cell

Infections, Leukemia, Lymphoma, Neoplasms, Neoplasms, Plasma Cell

NCT07202091 2025-10-07

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Immunoglobulin Stopping or Extension (Stop Ig)

Phase 2/3 Recruiting

LymphoidOther hematologic neoplasmPlasma cell

Infections, Leukemia, Lymphoma, Neoplasms, Neoplasms, Plasma Cell

NCT07156786 2025-09-19

N-Acetylcysteine Roles in Preserving Renal Function Measured by Urinary KIM-1 (Kidney Injury Molecule-1) and Serum Creatinine on Cancer Patients With Cisplatin Based Chemotherapy: A Randomized Placebo-Controlled Trial

Phase 2/3 Not yet recruiting

Neoplasms, Acute Kidney Injury

NCT06175273 2025-09-18

POINT

Phase 2/3 Completed

Muscular Atrophy, Neoplasms, Child Nutrition Disorders

NCT03653546 2025-09-10

BM

Phase 2/3 Completed

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms, Respiratory Tract Diseases

NCT03470922 2025-09-09

RELATIVITY-047

Phase 2/3 Active not recruiting

714 enrolled 17 charts 1 FDA

Melanoma, Neoplasms

NCT03348670 2025-08-17

Drugs-SNPs

Phase 2/3 Active not recruiting

Neoplasms, Prostatic Neoplasms

NCT01064466 2025-07-24

Drugs-SNPs

Phase 2/3 Active not recruiting

Neoplasms, Small Cell Lung Carcinoma

NCT04870333 2025-06-20

PROTECT-V

Phase 2/3 Completed

COVID-19, Glomerulonephritis, Lupus Erythematosus, Systemic, Neoplasms, Vasculitis

NCT02035098 2025-06-11

Improving Pain Management in Hospitalized Cancer Patients. A Before-after Cluster Phase II Trial

Phase 2/3 Completed

Neoplasms, Pain

NCT06028737 2025-05-06

OCTASUR

Phase 2/3 Recruiting

Gastrointestinal

Gastrointestinal Neoplasms, Neoplasms, Stomach Neoplasms

NCT00179855 2025-02-12

Extracorporeal Photopheresis for Acute Graft Versus Host Disease

Phase 2/3 Completed

Graft vs Host Disease, Neoplasms

NCT06782412 2025-02-07

FAPIDO

Phase 2/3 Recruiting

Gastrointestinal

Esophageal Neoplasms, Neoplasms, Stomach Neoplasms

NCT00179829 2025-02-04

WT1 for the Detection of Minimal Residual Disease

Phase 2/3 Completed

LymphoidMyeloidOther hematologic neoplasm

Leukemia, Neoplasms, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03512756 2024-11-06

A Randomized Phase 2/3 Multi-Center Study of SM-88 in Participants With Metastatic Pancreatic Cancer

Phase 2/3 Terminated

130 enrolled 13 charts

Gastrointestinal

Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms

NCT06672887 2024-11-04

MiLES

Phase 2/3 Recruiting

Neoplasms

NCT05678621 2024-04-19

RATIONALISE

Phase 2/3 Recruiting

LymphoidOther hematologic neoplasmPlasma cell

Agammaglobulinemia, Infections, Leukemia, Lymphoma, Neoplasms, Hematologic Neoplasms, Neoplasms, Plasma Cell

NCT06337695 2024-04-02

VERIFY: Vedolizumab for the Prevention of Immune Checkpoint Inhibitor Related Diarrhea or Colitis in Patients With Cancer

Phase 2/3 Not yet recruiting

Neoplasm Metastasis, Neoplasms

NCT05749302 2024-03-29

Application of Al18F-NOTA-FAPI PET/CT in Malignant Tumors Expressing Fibroblast-activated Proteins

Phase 2/3 Unknown

Neoplasms

NCT04987463 2024-02-08

ViRap

Phase 2/3 Unknown

Epilepsy, Neoplasms, Tuberous Sclerosis

NCT00584532 2023-11-24

GCP

Phase 2/3 Completed

Neoplasms, Prostatic Neoplasms

NCT06103279 2023-10-26

Cardioprotective Empagliflozin for Cancer Patients Receiving Doxorubicin

Phase 2/3 Unknown

Neoplasms

NCT03040726 2023-10-17

Netupitant and Palonosetron Hydrochloride in Preventing Chronic Nausea and Vomiting in Patients With Cancer

Phase 2/3 Completed

53 enrolled 15 charts

Nausea, Neoplasms, Vomiting